Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development

Asian Journal of Andrology

Volumn 13, Issue 4, 2011, Pages 628-629

  Stenman, Ulf Håkan ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; SERINE PROTEASE INHIBITOR KAZAL TYPE 1; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; ARTICLE; BREAST CANCER; CARCINOGENESIS; CASTRATION; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; TUMOR GROWTH;

EID: 79960040881     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.45     Document Type: Article

References (28)

1. Kazal LA, Spicer DS, Brahinsky RA. Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Am Chem Soc 1948; 70: 3034-40.
2. Bartelt DC, Shapanka R, Greene LJ. The primary structure of the human pancreatic secretory trypsin inhibitor. Amino acid sequence of the reduced Saminoethylated protein. Arch Biochem Biophys 1977; 179: 189-99. (Pubitemid 8047928)
3. Huhtala ML, Pesonen K, Kalkkinen N, Stenman UH. Purification and characterization of a tumorassociated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 1982; 257: 13713-6. (Pubitemid 13187134)
4. Stenman UH, Huhtala ML, Koistinen R, Seppala M. Immunochemical demonstration of an ovarian cancerassociated urinary peptide. Int J Cancer 1982; 30: 53-7. (Pubitemid 12044235)
5. Paju A, Stenman UH. Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor. Crit Rev Clin Lab Sci 2006; 43: 103-42. (Pubitemid 43860448)
6. Pfutzer RH, Barmada MM, Brunskill AP, Finch R, Hart PS et al. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 2000; 119: 615-23.
7. Stenman UH. Tumor-associated trypsin inhibitor. Clin Chem 2002; 48: 1206-9.
8. Paju A, Sorsa T, Tervahartiala T, Koivunen E, Haglund C et al. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br J Cancer 2001; 84: 1363-71. (Pubitemid 32522105)
9. Hotakainen K, Bjartell A, Sankila A, Jarvinen R, Paju A et al. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol 2006; 28: 95-101.
10. Wiksten JP, Lundin J, Nordling S, Kokkola A, Stenman UH et al. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Histopathology 2005; 46: 380-8. (Pubitemid 40516753)
11. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011; 3: 72ra17.
12. Ogawa M, Tsushima T, Ohba Y, Ogawa N, Tanaka S et al. Stimulation of DNA synthesis in human fibroblasts by human pancreatic secretory trypsin inhibitor. Res Commun Chem Pathol Pharmacol 1985; 50: 155-8. (Pubitemid 16231669)
13. Niinobu T, Ogawa M, Murata A, Nishijima J, Mori T. Identification and characterization of receptors specific for human pancreatic secretory trypsin inhibitor. J Exp Med 1990; 172: 1133-42. (Pubitemid 20343213)
14. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS et al. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 2007; 43: 736-44.
15. Gouyer V, Fontaine D, Dumont P, de Wever O, Fontayne-Devaud H et al. Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. Oncogene 2008; 27: 4024-33. (Pubitemid 351931988)
16. Gaber A, Johansson M, Stenman UH, Hotakainen K, Ponten F et al. High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer 2009; 100: 1540-8.
17. Gaber A, Nodin B, Hotakainen K, Nilsson E, Stenman UH et al. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. BMC Cancer 2010; 10: 498.
18. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V et al. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol 2007; 52: 1670-9.
19. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R et al. The role of SPINK1 in ETS rearrangementnegative prostate cancers. Cancer Cell 2008; 13: 519-28. (Pubitemid 351763901)
20. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL et al. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 2010; 16: 2845-51.
21. Normanno N, de Luca A, Bianco C, Strizzi L, Mancino M et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16. (Pubitemid 43199589)
22. Nabhan C, Lestingi TM, Galvez A, Tolzien K, Kelby SK et al. Erlotinib has moderate single-agent activity in chemotherapy-naive castration-resistant prostate cancer: final results of a phase II trial. Urology 2009; 74: 665-71.
23. Slovin SF, Kelly WK, Wilton A, Kattan M, Myskowski P et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2009; 7: E77-82.
24. Yasuda T, Ogawa M, Murata A, Ohmachi Y, Mori T et al. Identification of the IL-6-responsive element in an acute-phase-responsive human pancreatic secretory trypsin inhibitor-encoding gene. Gene 1993; 131: 275-80.
25. Lasson A, Borgstrom A, Ohlsson K. Elevated pancreatic secretory trypsin inhibitor levels during severe inflammatory disease, renal insufficiency, and after various surgical procedures. Scand J Gastroenterol 1986; 21: 1275-80. (Pubitemid 17199148)
26. Ogawa M, Matsuda K, Shibata T, Matsuda Y, Ukai T et al. Elevation of serum pancreatic secretory trypsin inhibitor (PSTI) in patients with serious injury. Res Commun Chem Pathol Pharmacol 1985; 50: 259-66. (Pubitemid 16212438)
27. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
28. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-9. (Pubitemid 29313142)